Scilex Holding (SCLX) Income from Continuing Operations (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Income from Continuing Operations of 45650000.0 for Q1 2026, down 75.04% year-over-year from 182880491.55 in Q1 2025, and up 0.99% on a QoQ basis from 46105000.0 in Q4 2025.
Scilex Holding (SCLX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Income from Continuing Operations for 7 consecutive years, with 45650000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 75.04% year-over-year to 45650000.0; the TTM figure through Mar 2026 stood at 393623000.0 (down 428.28% YoY), while the FY2025 annual figure was 374053000.0, down 413.76% from the prior year.
- Income from Continuing Operations came in at 45650000.0 for Q1 2026 at Scilex Holding, up from 46105000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 21501000.0 in Q3 2022, with the low at 257820000.0 in Q3 2025.
- Average Income from Continuing Operations over 5 years is 37070882.35, with a median of 26080000.0 recorded in 2025.
- The largest YoY upside for Income from Continuing Operations was 7736.6% in 2022 against a maximum downside of 10688.09% in 2022.
- Year by year, Income from Continuing Operations stood at 17884000.0 in 2022, then decreased by 19.66% to 21400000.0 in 2023, then jumped by 69.81% to 6460000.0 in 2024, then sank by 613.7% to 46105000.0 in 2025, then advanced by 0.99% to 45650000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 45650000.0, 46105000.0, and 257820000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.40 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 5.24 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 697.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 833.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | -45.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.65 Mn |
| Dec 31, 2025 | -46.11 Mn |
| Sep 30, 2025 | -257.82 Mn |
| Jun 30, 2025 | -44.05 Mn |
| Mar 31, 2025 | -26.08 Mn |
| Dec 31, 2024 | -6.46 Mn |
| Sep 30, 2024 | -4.39 Mn |
| Jun 30, 2024 | -37.58 Mn |
| Mar 31, 2024 | -24.38 Mn |
| Dec 31, 2023 | -21.40 Mn |
| Sep 30, 2023 | -35.53 Mn |
| Jun 30, 2023 | -26.65 Mn |
| Mar 31, 2023 | -30.75 Mn |
| Dec 31, 2022 | -17.88 Mn |
| Sep 30, 2022 | 21.50 Mn |
| Jun 30, 2022 | -17.84 Mn |
| Mar 31, 2022 | -9.14 Mn |
| Dec 31, 2021 | -35.26 Mn |
| Sep 30, 2021 | -281,552.00 |
| Jun 30, 2021 | -165,349.00 |